Hematologic Malignancies
6.5
credits/contact hours
Register Now |  Learning Objectives |  Registration Fee |  Agenda |  Accreditation

Learn From the Experts About
Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Gain insights and clinical knowledge on the science of new targeted therapies and immunotherapies for the treatment of hematologic malignancies. Learn how to manage the side effects and other clinical issues associated with these new treatments in a case-based, informal educational setting. 

Pittsburgh, PA • October 20, 2018

Herberman Conference Center
5150 Centre Ave.
2nd Floor
Pittsburgh, PA 15232
Register Now

LEARNING OBJECTIVES

Diffuse Large B-Cell Lymphoma (DLBCL)

  • Describe the current treatments for early stage DLBCL
  • Describe the current treatments for relapsed/refractory DLBCL
  • Discuss the emerging therapies, their potential adverse events and the associated clinical trials underway for DLBCL
  • Describe appropriate patient selection criteria for CAR-T therapy
  • Recall the strategies to mitigate for the potential of cytokine release syndrome and other serious side effects with CAR-T therapy

 Mantle Cell Lymphoma (MCL)

  • Describe the latest information on risk stratification of patients with MCL
  • Identify appropriate usage of new agents in the treatment of MCL
  • Describe how to best manage treatment side effects for patients with MCL

 Acute Myeloid Leukemia (AML)

  • Discuss newly approved and investigational therapies and clinical trials for AML
  • Describe mitigation strategies to manage side effects of emerging therapies in AML
  • Discuss advancements in diagnostic tests used in risk stratification for AML including next-generation sequencing (NGS) for the discovery of novel molecular abnormalities as defined by the World Health Organization (WHO) and European Leukemia Network
  • Discuss management of minimal residual disease

Chronic Lymphocytic Leukemia (CLL)

  • Recall high-risk CLL determinants including clinical factors, biologic and genetic factors, and complex karyotypes
  • Incorporate emerging therapies into treatment plans for patients with CLL, based upon an evaluation of efficacy and safety, as well as patient age, performance status and comorbidities
  • Integrate mitigation strategies into treatment planning for managing adverse events such as patient education, prophylactic measures and dose adjustments in CLL

Follicular Lymphoma

  • Describe prognostic factors and risk adaptive strategies for treatment decisions in follicular lymphoma
  • Discuss the latest data on efficacy and safety of newly approved agents for primary, relapsed, and refractory follicular lymphoma
  • Formulate strategies to manage treatment side effects for patients with follicular lymphoma
  • Recall clinical trials of novel targeted therapies for the management of newly diagnosed and relapsed/refractory follicular lymphoma

Myeloproliferative Neoplasms (MPNs)

  • Describe the latest WHO disease definitions for diagnosing myeloid malignancies
  • Discuss the normal physiology of the JAK-STAT biochemical signaling pathway, as well as its dysregulation in myeloproliferative neoplasms
  • Identify germline mutations in patients with predisposition for MPN/MDS

Multiple Myeloma

  • Evaluate safety and efficacy data of emerging therapies for the treatment of multiple myeloma
  • Formulate strategies for patient care for patients requiring maintenance therapy or relapsed/refractory multiple myeloma
  • Evaluate use of monoclonal antibodies for the treatment of multiple myeloma, particularly mechanism of action, administration and dosing, and side effect management

Hodgkin Lymphoma

  • Discuss emerging therapies for for treatment of relapsed refractory classic Hodgkin lymphoma (cHL)
  • Discuss the mechanism of action and use of PD-1 inhibitors in the treatment of cHL
  • Describe clinical trials underway in cHL
  • Discuss strategies to manage adverse events and reduce short- and long-term treatment-related toxicities of existing regimens for cHL

 

REGISTRATION FEE

  Member Non-Member
Registration $50.00 $75.00

AGENDA

7:00 am Registration
7:30 am Breakfast
8:30 am Welcome and Introductions
8:45 am Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents – 1.50 Contact Hours
  • Diffuse large B-cell lymphoma
    • WHO classification system
    • Risk stratification
      • Double hit/triple hit
    • Immunotherapy/adoptive cell therapy (CAR-T)
      • Mechanisms of action
      • Patient selection
      • Program requirements and clinical management
  • Mantle cell lymphoma
    • Risk stratification
    • Emerging therapies: BTK inhibition, proteasome inhibitors, immunomodulatory agents, PI3K, BCL2, and monoclonal antibodies
    • Clinical management
10:15 am Break
10:30 am Acute Myelogenous Leukemia – 1.50 Contact Hours
  • Updated WHO criteria
  • Risk stratification and response evaluation
    • NGS to diagnose AML
    • Minimal residual disease
    • Treatment-related AML
    • AML with antecedent hematologic malignancies (myelodysplastic syndrome, MPN)
    • AML in the elderly
  • Novel and emerging therapies
    • Targeted therapies: IDH2, FLT3, BCL2, CD33, CD123, and investigational agents
  • Clinical management 
12:00 pm Lunch Break
1:00 pm Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents  – 1.00 Contact Hour
  • Chronic lymphocytic leukemia: Risk stratification
  • Novel and emerging therapies/combination therapies
    • BTK, BCL2, PI3K, SYK, and monoclonal antibodies
  • Clinical management
  • Follicular lymphoma: Risk stratification
  • Novel and emerging therapies/combination therapies
    • PI3K and monoclonal antibodies
  • Clinical management
2:00 pm Myeloproliferative Neoplasms (MPN) – 1.00 Contact Hour
  • WHO classification system
    • Polycythemia vera (PV)
    • Essential thrombocythemia (ET)
    • Primary myelofibrosis/post PV MF, post ET MF
  • Novel therapies
    • Targeting the JAK-STAT pathway
  • Evaluating disease response/intolerance
  • Clinical management
3:00 pm Break
3:15 pm Updates in Multiple Myeloma – 1.00 Contact Hour
  • Risk stratification
  • Novel therapies: IMiDs/proteasome inhibitors/immunotherapy
  • Clinical management
4:15 pm Relapsed/Refractory Hodgkin Lymphoma – 0.50 Contact Hour
  • Novel therapies: Targeting PD-L1 and CD30
  • Management of treatment-related toxicities
4:45 pm Program Adjourns

*Subject to change

Pittsburgh, PA • October 20, 2018

Herberman Conference Center
5150 Centre Ave.
2nd Floor
Pittsburgh, PA 15232
Register Now

AGENDA


Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 6.5 contact hours may be earned for successful completion of this activity.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-18-034-L01-P.

This program is designated for up to 6.5 contact hours (0.650 CEUs) of continuing pharmacy education credit.

PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

PAs may receive a maximum of 6.5 Category 1 credits for completing this activity.

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

This CME/CE/CPE accredited conference is jointly provided by